Observational analysis shows progression of diastolic dysfunction in mice with diabetic cardiomyopathy, indicating that it mimics features of human disease.
Key Points
HFD/STZ mice exhibited progressive diastolic dysfunction, alongside features of metabolic inflammation and LV remodelling.
Levels of HbA1c and fasting blood glucose were significantly elevated in HFD/STZ mice compared to controls.
This modified model provides a clinically relevant platform for preclinical evaluation of therapies targeting diabetic cardiomyopathy.
Findings suggest a triple-hit mechanism involving type 2 diabetes, diastolic dysfunction, and inflammation in DbCM progression.